The Poor Responders Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

220 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-08-01

Study Completion Date

2027-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Obesity and type 2 diabetes are major causes of illness and premature death worldwide and their incidence is increasing rapidly. Bariatric surgery is considered as the "gold-standard" surgical treatment for both conditions.

However, not all patients do equally well after surgery and indeed the weight loss experienced by patients undergoing bariatric surgery can vary. As such when patients are seen after bariatric surgery in clinic they fall in one of the following two categories:

1. Good responders: this is the majority of patients who lose the expected amount of weight based on the published studies.
2. Poor responders: this is a small group of patients who either lose less than the expected amount of weight after bariatric surgery or lose the expected amounts of weight early after surgery but then regain a substantial proportion of the weight they have lost.

The so-called "poor responders" are exposed to all the risks of the operation and do not benefit from the weight loss as much as good responders.

This study would therefore like to investigate the physiological factors that distinguish poor from good responders before, and after bariatric surgery. The study team hypothesizes that compared to good responders, poor responders exhibit:

1. a smaller degree of fullness sensation after a meal,
2. a lower energy expenditure after a meal, and
3. genetic changes (single nucleotide polymorphisms) that predispose the poor responder to development of obesity.

In addition, the study team hypothesizes that poor responders exhibit:

1. lower gut hormone secretion after a meal and
2. are less sensitive to the physiological action of gut hormones compared to good responders and that this difference in gut hormone secretion and response to gut hormones prior to bariatric surgery can be helpful to predict response to bariatric surgery.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Causal Effect of Bariatric Surgery on Cardiovascular Disease and Mortality

NCT06420479

Bariatric Surgery Candidate Cardiovascular Diseases Morality

RECRUITING

Comparing Bariatric Surgery Outcomes in Predominantly High-Risk Asian Patients to Global Benchmarks

NCT06649578

Bariatric Surgery Cost of Care Complications

COMPLETED

Who Will Benefit From Bariatric Surgery for Diabetes?

NCT03842475

Diabetes Mellitus, Type 2 Obesity

RECRUITING

Obesity and Health-related Quality of Life in Patients Receiving Bariatric Surgery in the UK

NCT06324526

Quality of Life Obesity, Morbid Bariatric Surgery Candidate

COMPLETED

Effect of Obesity, Diabetes and Bariatric Surgery on Pregnancy Outcomes

NCT05753124

Obesity Pregnancy in Diabetic Pregnancy Complications +2 more

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bariatric Surgery Candidate Obesity, Morbid Diabetes Mellitus, Type 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Gut hormone secretion study

This will be a retrospective study of participants who have undergone bariatric surgery. On the day of the visit participants will undergo comprehensive physiological profiling which will include the following tests:

* Body weight and bioelectrical impedance analysis
* Mixed Meal Tolerance Test. This will be analysed for metabolites including gut hormones, insulin, glucose, bile acids and their sub-fractions, fibroblast-growth factors, lipids and immune profiles.
* Resting Energy Expenditure and Diet Induced Thermogenesis assessed via Indirect Calorimetry
* Metabolomic and Metagenomic Assessment

Group Type NO_INTERVENTION

No interventions assigned to this group

Gut hormone sensitivity study

This will be a single blinded study with participants attending three visits. Their first visit will act as an acclimatisation visit and participants will be infused subcutaneously with a triple gut hormone infusion (GLP-1, PYY and OXM). This will not only allow us to acclimatise the study volunteer to the study visits, but also allow us to test for subject tolerability of the gut hormones. Occasionally some volunteers are more sensitive to the gut hormone infusion and the doses needs to be titrated down. The doses used will be established doses of the gut hormones infused previously and which have been shown to be safe and tolerated, and to reduce appetite (In house data).

Group Type PLACEBO_COMPARATOR

Gut hormones

Intervention Type OTHER

Their first visit will act as an acclimatisation visit and participants will be infused subcutaneously with a triple gut hormone infusion (GLP-1, PYY and OXM). This will not only allow us to acclimatise the study volunteer to the study visits, but also allow us to test for subject tolerability of the gut hormones.

For the next two visits participants will be randomised in a single-blinded fashion to a subcutaneous infusion of either:

1. 0.9% saline,
2. GLP-1

Prospective assessment of gut hormone response pre and post-surgery

This will be a prospective study assessing the gut hormone response pre and post bariatric surgery.

On the day of the visit participants will undergo comprehensive physiological profiling which will include the following tests:

* Body weight and bioelectrical impedance analysis
* Mixed Meal Tolerance Test. This will be analysed for metabolites including gut hormones, insulin, glucose, bile acids and their sub-fractions, fibroblast-growth factors, lipids and immune profiles.
* Resting Energy Expenditure and Diet Induced Thermogenesis assessed via Indirect Calorimetry
* Metabolomic and Metagenomic Assessment

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Gut hormones

Their first visit will act as an acclimatisation visit and participants will be infused subcutaneously with a triple gut hormone infusion (GLP-1, PYY and OXM). This will not only allow us to acclimatise the study volunteer to the study visits, but also allow us to test for subject tolerability of the gut hormones.

For the next two visits participants will be randomised in a single-blinded fashion to a subcutaneous infusion of either:

1. 0.9% saline,
2. GLP-1

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 18 -70 years.
* Male or female.
* Previous bariatric surgery for obesity and/or diabetes (studies 1 and 2).
* ≥1 year interval after bariatric surgery (studies 1 and 2).
* Awaiting bariatric surgery at the Imperial Weight Centre (study 3)
* Able to give informed consent.

Exclusion Criteria

* History of any medical, psychological or other condition, or use of any medications, including over-the-counter products, which, in the opinion of the investigators, would either interfere with the study or potentially cause harm to the volunteer.
* Without access at home to a telephone or other factor likely to interfere with ability to participate reliably in the study.
* Pregnancy or breastfeeding.
* Unable to maintain adequate contraception for the duration of the study and for one month afterwards.
* History of hypersensitivity to any of the components of the subcutaneous infusions.
* Donated blood during the preceding 3 months or intention to do so before the end of the study.
* Any other co-morbidity that would compromise the validity of the study or the safety of the participant such as heart failure or clinically apparent cardiovascular disease.
* Anatomical or endocrinological pathology causing poor weight loss or weight regain
* Uncontrolled hypertension (systolic blood pressure of 160 mmHg or above and/or diastolic blood pressure of 100 mmHg or above)
* Participation in a research study within the last two months.
* Unable to speak English (this is relevant to answering the psychological questionnaires)

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No